Navigation Links
Ebola DNA vaccine produces immune responses in all fully vaccinated volunteers in Phase 1 trial

Vical Incorporated announced today that an Ebola vaccine candidate administered using Vical's proprietary DNA delivery technology was safe and well tolerated, and produced both antibody and T-cell Ebola-specific responses in all healthy volunteers who received the full 3 doses of vaccine.

The Phase 1, randomized, placebo-controlled, dose-escalation study, the first human trial for any Ebola vaccine, was sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), and conducted at the NIH Clinical Center. The data were presented at the American Society for Microbiology (ASM) 2006 Biodefense Research Meeting in Washington, D.C., by Julie E. Martin, D.O., a trial investigator and research scientist at NIAID's Dale and Betty Bumpers Vaccine Research Center (VRC), which developed the vaccine. The DNA vaccine used in the Phase 1 trial incorporates genetic material encoding core and surface proteins from two strains of Ebola. Vical has secured a nonexclusive license from the NIH to proprietary gene sequences used in the vaccine.

"The high rates of immune responses at all dose levels in this initial human Ebola vaccine study support continued development of this vaccine and further evaluation of our technology for potential additional biodefense and emerging disease applications," said David C. Kaslow, M.D., Vical's Chief Scientific Officer, "particularly where antibody responses may be protective. Our processes allow rapid development and manufacturing of vaccines without handling potentially dangerous pathogens."

The vaccine used in the Phase 1 trial vaccine included three plasmids (closed loops of DNA), one each encoding the surface glycoprotein (GP) from the Zaire strain of Ebola, GP from the Sudan/Gulu strain, and the internal nucleoprotein (NP) from the Zaire strain. Subjects received three doses of vaccine or placebo at one-month intervals via intramuscular needleless injection. Three coh orts tested progressively higher doses of the vaccine at 2 mg (5 subjects), 4 mg (8 subjects), or 8 mg (8 subjects ?with 6 receiving the full three doses). Each cohort included two additional subjects who received placebo instead of active vaccine.

The vaccine was well tolerated, with no severe adverse reactions to the vaccine reported at any of the doses tested. Ebola-specific antibody responses against at least one of the encoded antigens were detected in all vaccine recipients. GP-specific antibody and T-cell responses were detected in all recipients who received the full three doses at all dose levels.


Source:Porter Novelli, Life Sciences

Related biology news :

1. Study Links Ebola Outbreaks To Animal Carcasses
2. Scientists discover how Ebola virus infects cells
3. Ebola virus: from wildlife to dogs
4. Poaching, logging, and outbreaks of Ebola threaten central African gorillas and chimpanzees
5. Gene-specific Ebola therapies protect non-human primates from lethal disease
6. Gorilla susceptibility to Ebola virus: the cost of sociality
7. Researchers discover key mechanism by which lethal viruses Ebola and Marburg cause disease
8. Pattern of human Ebola outbreaks linked to wildlife and climate
9. Ebola-outbreak kills 5000 gorillas
10. Ebola outbreaks killing thousands of gorillas and chimpanzees
11. Research advances quest for HIV-1 vaccine
Post Your Comments:

(Date:11/17/2015)... , November 17, 2015 Paris ... 2015.   --> Paris from 17 ... DERMALOG, the biometrics innovation leader, has invented the first ... fingerprints on the same scanning surface. Until now two different ... Now one scanner can capture both on the same ...
(Date:11/12/2015)... 12, 2015  A golden retriever that stayed healthy ... (DMD) has provided a new lead for treating this ... Broad Institute of MIT and Harvard and the University ... Cell, pinpoints a protective gene ... disease,s effects. The Boston Children,s lab of Lou ...
(Date:11/10/2015)... 2015 About signature verification ... to identify and verify the identity of an ... the secure and accurate method of authentication and ... individual because each individual,s signature is highly unique. ... dynamic signature of an individual is compared and ...
Breaking Biology News(10 mins):
(Date:11/30/2015)... Nov. 30, 2015 Spherix Incorporated (Nasdaq: ... to the fostering and monetization of intellectual property, ... prospective initiatives designed to create shareholder value. ... of Spherix. "Based on published reports, the total ... $50 billion and Spherix will seek to secure ...
(Date:11/30/2015)... , Nov. 30, 2015  HUYA Bioscience International, ... China,s pharmaceutical innovations, today announced it has ... Development Fund (KDDF) to foster collaboration between KDDF and ... and commercialization of healthcare products for the global market. ... an important source of new innovative preclinical and clinical ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... announced tighter software integration with MarkLogic, the Enterprise NoSQL database platform provider, ... to drive change. , Smartlogic’s Content Intelligence capabilities provide a robust set ...
(Date:11/27/2015)... , November 27, 2015 ... Growing popularity of companion diagnostics is one ... biomarkers market with pharmaceutical companies and diagnostic ... diagnostic tests. . ... Complete report on global cancer biomarkers market ...
Breaking Biology Technology: